A detailed history of Covington Capital Management transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Covington Capital Management holds 495 shares of CRSP stock, worth $25,165. This represents 0.0% of its overall portfolio holdings.

Number of Shares
495
Previous 495 -0.0%
Holding current value
$25,165
Previous $30,000 6.67%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 08, 2022

BUY
$43.23 - $73.83 $4,323 - $7,383
100 Added 25.32%
495 $30,000
Q2 2020

Aug 13, 2020

BUY
$38.5 - $76.05 $770 - $1,521
20 Added 5.33%
395 $29,000
Q1 2020

May 13, 2020

SELL
$33.68 - $62.53 $6,736 - $12,506
-200 Reduced 34.78%
375 $16,000
Q3 2018

Nov 15, 2018

BUY
$44.35 - $65.71 $8,870 - $13,141
200 Added 53.33%
575 $26,000
Q1 2018

May 11, 2018

BUY
$23.52 - $58.17 $4,116 - $10,179
175 Added 87.5%
375 $17,000
Q3 2017

Nov 14, 2017

BUY
$16.75 - $20.66 $3,350 - $4,132
200
200 $4,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.97B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Covington Capital Management Portfolio

Follow Covington Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Covington Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Covington Capital Management with notifications on news.